Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$295.10 USD

295.10
1,231,097

-2.54 (-0.85%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $295.07 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.

Zacks Equity Research

Charles River (CRL) Launches LVV-based Gene Therapy Platform

by Zacks Equity Research

Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.

Zacks Equity Research

Charles River (CRL) Opens a RightSource Lab in Stevenage

by Zacks Equity Research

Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.

Zacks Equity Research

Charles River (CRL) Announces Partnership With Related Sciences

by Zacks Equity Research

Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.

Zacks Equity Research

Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.

Zacks Equity Research

Charles River (CRL) Gains From Global Demand Amid FX Woes

by Zacks Equity Research

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Zacks Equity Research

Charles River (CRL) Collaborates With Fondazione Telethon

by Zacks Equity Research

Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.

Zacks Equity Research

Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed

by Zacks Equity Research

Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.

Zacks Equity Research

Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings

by Zacks Equity Research

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.